Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical update. J Clin Oncol. 2024;42(suppl 16):3083. doi:10.1200/JCO.2024.42.16_suppl.3083 A study of NDI 1150-101 in patients with solid tumors. ClinicalTrials.gov. Updat...
Clinical Trial Registration Number:NCT05315167 发布日期:2024.05 摘要号:2590 YF550-C1小分子抑制剂研究摘要海报细节展示如下: 题目: YF550-C1, an E3 ligase inhibitor of Cbl-b, to demonstrate T cell and NK cell ac-tivation and anti-tumor activities in syngeneic and PDX tumor model 网页链接: https...
BeiGene, a commercial-stage biotechnology company, announced that the first patient has been dosed in a phase 1 clinical trial of BGB-15025, its investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor. BGB-15025 is designed to be a potent and highly selective small molecule oral inhibit...
small molecule inhibitorclinical trialIntroduction Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-related protein kinase, functions as an intracellular negative regulator, primarily in hematopoietic lineage cells, where it regulates T cells, B cells, dendritic cells, and other...
Nimbus’ pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, autoimmune conditions and metabolic diseases. Nimbus is headquartered in Boston, Mass. To learn more about Nimbus, please ...
TWT-101: a first-in-clinic, phase 1/2 study of CFI-402411, a hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies. Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC...
Background CFI-402411 is a potent inhibitor of HPK1 (Hematopoietic progenitor kinase 1), a protein serine/threonine kinase that negatively-regulates T-cell activation. Following T-cell receptor engagement, HPK1 phosphorylates SLP-76, to down-regulate signals required for T-cell activation and ...
BGB-15025, a potent, selective, small-molecule HPK1 inhibitor, showed preliminary antitumor effects in preclinical studies as monotherapy (mono tx) and enhanced antitumor effects in combination with TIS. We present dose-escalation results from an open-label, multicenter, phase 1 study (NCT04649385)...
Interestingly, HZ-S506 possessed excellent pharmacokinetic properties, the exposure of which is higher than its parent inhibitor (~2 folds). In efficacy studies, HZ-S506 exhibited anti-tumor activity CT26 tumor model as single agent and in combination with an anti-PD1 antibody, demonstrated robust...
BGB-15025 is currently in phase I clinical trial to treat patients with advanced solid tumor, both as a single agent and in combination with anti PD-1 antibody tislelizumab.Ye LiuJing LiZhuo LiQin WangXing ZhouXiaoxin LiuBo ZhangXitao Wang...